The main treatment options for patients with chronic Chikungunya fever symptoms

Batista, M. C. ¹; Silveira, L. P. O. S ²; Soares, M. A. G. ³; Ramos, R. C. F. 4

1, 2, 3Estudante do Curso de Medicina – Unicap; 4 Pesquisador do Hospital Oswaldo Cruz, Depto de Infectologia Pediátrica.

Introduction: Chikungunya fever is a disease caused by the chikungunya virus (CHIKV) and is transmitted by arthropod bites, mainly by the species Aedes aegypti and Aedes albopictus. It became an epidemic in 2005, reaching, afterwards, America, including Brazil, with intense consequences for its population. Its spectrum of manifestation includes three phases: acute, subacute and chronic, in addition to some reports of atypical cases. Little is known about its pathophysiology, fact that turns it into an area of extreme research. Objectives: Carry out a literature review about the main treatment options for patients with chronic Chikungunya fever symptoms. Methodology: A literature review was carried out covering articles from the last 10 years (2007 to 2017), selected through a search in the PUBMED database, using the descriptor “Febre Chinkungunya”. Results and Conclusion: Regarding the treatment, it was seen that there is still no specific drug, despite the studies, using purely symptomatic drugs, with increasing doses based on the clinical phase presented.

Keywords:  Arbovirus infections; Chikungunya Fever; Chikungunya virus

Free Full-text PDF

How to cite this article:
Batista, M. C.; Silveira, L. P. O. S; Soares, M. A. G.; Ramos, R. C. F. The main treatment options for patients with chronic Chikungunya fever symptoms.American Journal of Ophthalmic Research and Reviews, 2018, 1:2. DOI:10.28933/ajoorr-2018-06-1802

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details)

CC BY 4.0
This work and its PDF file(s) are licensed under a Creative Commons Attribution 4.0 International License.